HolderBook

Commodore Capital LP

Reported holdings as of Q2 2026, from 23 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1831942
Reported value
$1.7B
Positions
33
Top 10 weight
68.2%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
RELAY THERAPEUTICS INCRLAY$224.5M12,000,00013.37%+3.59pp5q-29.4%-$93.5M
ENLIVEN THERAPEUTICS INCELVN$166.2M3,275,0009.90%+2.47pp14qHELD
ALKERMES PLCALKS$157.2M3,000,0009.36%+0.77pp9q-28.6%-$62.9M
COGENT BIOSCIENCES INCCOGT$118.0M3,050,0007.03%+0.60pp23q+5.6%+$6.3M
AMYLYX PHARMACEUTICALS INCAMLX$101.5M5,650,0006.04%+1.50pp4qHELD
DEFINIUM THERAPEUTICS INCDFTX$94.1M2,000,0005.60%+3.42pp2qHELD
SPYRE THERAPEUTICS INCSYRE$75.2M846,7864.48%-1.10pp12q-55.7%-$94.6M
ALTO NEUROSCIENCE INCANRO$71.9M2,723,1964.28%+0.74pp3qHELD
TANGO THERAPEUTICS INCTNGX$70.3M2,250,0004.19%-newNEW
EYEPOINT INCEYPT$65.8M4,600,0003.92%+1.81pp2q+62.8%+$25.4M
TYRA BIOSCIENCES INCTYRA$59.9M1,875,0003.57%-1.92pp6q-24.2%-$19.2M
DAMORA THERAPEUTICS INCDMRA$50.4M1,939,0003.00%+0.10pp2qHELD
CELLDEX THERAPEUTICS INC NEWCLDX$50.2M1,350,0002.99%-1.96pp6q-49.9%-$50.1M
PHARVARIS N VPHVS$49.3M1,425,0002.93%-0.20pp11q-25.7%-$17.1M
LB PHARMACEUTICALS INCLBRX$48.7M1,500,0002.90%+0.76pp4qHELD
ASSEMBLY BIOSCIENCES INCASMB$38.9M1,415,0002.32%+0.71pp4q+41.5%+$11.4M
EDITAS MEDICINE INCEDIT$28.8M8,889,0001.72%-newNEW
KYMERA THERAPEUTICS INCKYMR$28.7M250,0001.71%-1.91pp5q-66.7%-$57.3M
PERSPECTIVE THERAPEUTICS INCCATX$21.6M6,336,7821.29%-0.24pp2qHELD
CENTURY THERAPEUTICS INCIPSC$21.3M8,695,6521.27%+0.13pp2qHELD
ZURA BIO LTDZURA$19.2M3,250,0001.14%+0.02pp2qHELD
AVALO THERAPEUTICS INCAVTX$18.8M1,018,3191.12%+0.70pp9q+110.8%+$9.9M
INFLARX NVIFRX$16.4M7,300,0000.97%-newNEW
AN2 THERAPEUTICS INCANTX$14.2M2,933,6800.85%+0.38pp2q+25.7%+$2.9M
NUVALENT INCNUVL$12.3M100,0000.74%-4.21pp15q-88.0%-$90.6M
SAB BIOTHERAPEUTICS INCSABS$11.2M2,870,0000.67%-0.31pp4q-34.8%-$6.0M
INHIBIKASE THERAPEUTICS INCIKT$11.0M5,397,4880.65%+0.13pp7qHELD
RELMADA THERAPEUTICS INCRLMD$9.9M1,425,0000.59%+0.33pp2q+124.8%+$5.5M
PEPGEN INCPEPG$8.1M4,475,0000.48%+0.02pp4qHELD
RESEARCH ALLIANCE CORP IIIRACC$5.3M500,0000.32%-newNEW
HELIX ACQUISITION CORP IIIHLXC$5.3M500,0000.32%+0.02pp2qHELD
LEONABIO INCLONA$4.3M464,3980.25%-0.02pp3qHELD
VISTAGEN THERAPEUTICS INCVTGN$630.2K2,788,6200.04%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 98.6%Other sectors 0.3%Not classified 1.1%
 
SectorValueShare
Biotech & Pharma$1.7B98.6%
Other sectors$5.3M0.3%
Not classified$17.7M1.1%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+31.5%+14.8%+16.6%99%
Q1 2026+23.0%-4.6%+27.7%98%
Q4 2025+32.7%+2.4%+30.4%100%
Q3 2025+35.9%+7.8%+28.0%100%
Q2 2025+7.3%+10.5%-3.2%100%
Q1 2025-16.9%-4.6%-12.4%100%
Q4 2024-17.2%+2.1%-19.3%100%
Q3 2024+12.4%+5.4%+7.0%100%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$1.7B33569868.2%45
Q1 2026$1.7B3613761061.3%45
Q4 2025$1.5B3364121055.8%48
Q3 2025$2.0B37799358.9%45
Q2 2025$1.4B33798562.2%45
Q1 2025$1.4B314134465.0%45
Q4 2024$1.4B314108969.8%45
Q3 2024$1.6B364129360.8%45
Q2 2024$1.5B355155963.8%45
Q1 2024$1.5B39121111560.2%45
Q4 2023$1.1B32877663.0%45
Q3 2023$855.5M30893465.1%45
Q2 2023$889.8M262142874.1%45
Q1 2023$656.8M324155766.4%45
Q4 2022$663.5M351187661.0%45
Q3 2022$621.9M301033469.7%45
Q2 2022$473.0M243114675.6%46
Q1 2022$447.7M27493271.5%46
Q4 2021$431.8M253102772.7%45
Q3 2021$379.3M296142663.9%46
Q2 2021$287.0M293144559.1%106
Q1 2021$251.0M317117455.6%197
Q4 2020$183.9M28000054.8%47

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.